Evidence map›Paper›PMID 40199537›Full record

ArticleNeurosciences (Riyadh, Saudi Arabia)2025

Do people with multiple sclerosis in Saudi Arabia want to know their prognosis? A cross-sectional nationwide study.

Yaser M Al Malik, Awad S Alharbi, Mohammed A Alfurayh, Abdulaziz A Aldalaan, Abdulazeez M Alzailaie, Eid D Alanazi, Ahmad A Abulaban, Seraj O Makkawi, Asma A Alanazi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurosciences (Riyadh, Saudi Arabia), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yaser M Al MalikFrom the College of Medicine (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), from the Department of Neurology (Al Malik, Abulaban), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Riyadh, from College of Medicine (Makkawi), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Makkawi), and from the Department of Neuroscience (Makkawi), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah, Kingdom of Saudi Arabia.ORCID https://orcid.org/0000-0002-9239-2691
Awad S AlharbiFrom the College of Medicine (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), from the Department of Neurology (Al Malik, Abulaban), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Riyadh, from College of Medicine (Makkawi), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Makkawi), and from the Department of Neuroscience (Makkawi), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah, Kingdom of Saudi Arabia.
Mohammed A AlfurayhFrom the College of Medicine (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), from the Department of Neurology (Al Malik, Abulaban), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Riyadh, from College of Medicine (Makkawi), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Makkawi), and from the Department of Neuroscience (Makkawi), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah, Kingdom of Saudi Arabia.
Abdulaziz A AldalaanFrom the College of Medicine (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), from the Department of Neurology (Al Malik, Abulaban), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Riyadh, from College of Medicine (Makkawi), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Makkawi), and from the Department of Neuroscience (Makkawi), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah, Kingdom of Saudi Arabia.
Abdulazeez M AlzailaieFrom the College of Medicine (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), from the Department of Neurology (Al Malik, Abulaban), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Riyadh, from College of Medicine (Makkawi), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Makkawi), and from the Department of Neuroscience (Makkawi), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah, Kingdom of Saudi Arabia.
Eid D AlanaziFrom the College of Medicine (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), from the Department of Neurology (Al Malik, Abulaban), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Riyadh, from College of Medicine (Makkawi), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Makkawi), and from the Department of Neuroscience (Makkawi), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah, Kingdom of Saudi Arabia.
Ahmad A AbulabanFrom the College of Medicine (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), from the Department of Neurology (Al Malik, Abulaban), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Riyadh, from College of Medicine (Makkawi), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Makkawi), and from the Department of Neuroscience (Makkawi), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah, Kingdom of Saudi Arabia.
Seraj O MakkawiFrom the College of Medicine (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), from the Department of Neurology (Al Malik, Abulaban), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Riyadh, from College of Medicine (Makkawi), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Makkawi), and from the Department of Neuroscience (Makkawi), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah, Kingdom of Saudi Arabia.
Asma A AlanaziFrom the College of Medicine (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Al Malik, Alharbi, Alfurayh, Aldalaan, Alzailaie, Alanazi, Abulaban, Alanazi A), from the Department of Neurology (Al Malik, Abulaban), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Riyadh, from College of Medicine (Makkawi), King Saud bin Abdulaziz University for Health Sciences, from King Abdullah International Medical Research Center (Makkawi), and from the Department of Neuroscience (Makkawi), King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah, Kingdom of Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate whether Persons with MS (pwMS) in Saudi Arabia want to discuss their long-term prognosis (LTP) and the factors influencing this decision using a self-administered online questionnaire.

methodsIn this cross-sectional study, an online questionnaire was distributed from December 2022 to July 2023 across Saudi Arabia to determine pwMS interest in discussing their LTP. Participants included patients over 18 years, of any gender, diagnosed with MS. A nonprobability convenience sampling technique was used, with questionnaires sent through MS organizations and channels.

resultsAlmost two-thirds (66-68%) of the 375 respondents reported that their LTP had never been discussed during neurologist appointments and expressed uncertainty about it. Additionally, 23.5% noted discrepancies in information provided by different neurologists. Most (81.6%) expressed a desire for a prognostic tool at diagnosis. In this study, MS patients' desire to learn about a tool for assessing long-term prognosis was significantly associated with age, education level (

conclusionWhile more than half of pwMS are curious about their prognosis, only about one-third have optimal discussions about LTP with neurologists. Many desire information on prognostic tools. Further research is needed to assess patients' knowledge of their prognosis and improve communication with physicians.

Indexed as

Multiple SclerosisAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedPrognosisSaudi ArabiaSurveys and QuestionnairesYoung Adult

Identifiers

PMID40199537
PMCPMC11977590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.